Implementation of a large liquid biopsy genomic profiling assay in a decentralized setting - Summary - MDSpire
From the Journals

Implementation of a large liquid biopsy genomic profiling assay in a decentralized setting

In this webinar, Dr. Gang Zheng MD, PhD, will share experience from the Mayo Clinic laboratory, how the lab approaches liquid biopsy and recent implementation data of a liquid biopsy assay to enable comprehensive genomic profiling (CGP).

  • April 30, 2026

Share

Large panel liquid biopsy assays, encompassing over 300 genes, are evolving in the clinical landscape due to technical advancements and decreasing costs per sample. Laboratories are beginning to incorporate these assays for comprehensive genomic profiling (CGP) as they offer shorter turnaround times compared to traditional FFPE tissue methodologies. Dr. Gang Zheng from the Mayo Clinic discusses their experiences, including performance metrics of their TSO 500 ctDNA v2 assay, which utilizes blood and CSF to ensure accurate variant reporting and facilitate research applications.

Original Source(s)

Implementation of a large liquid biopsy genomic profiling assay in a decentralized setting

  • April 30, 2026

Related Content

This Week’s Biopharma News: KRAS Breakthrough and ADC Momentum

Revolution’s KRAS breakthrough, strong ADC signals from GSK, and shifting regulatory and dealmaking dynamics define this week in biopharma

  • April 21, 2026

  • 4 min
Modeling the Genetics of Uveal Melanoma

Researchers have developed a genetically engineered mouse model that mirrors the genetic evolution of uveal melanoma

  • April 21, 2026

  • 3 min
This Week’s CGT News: New FDA Genome Editing Guidance 

Our latest roundup highlights tighter FDA expectations for genome editing safety, advances in CRISPR precision and delivery, and continued momentum for off-the-shelf CAR-T

  • April 20, 2026

  • 6 min